Market Place
Sourcing Support
Takeda Ends Partnership With Veritas In Silico For mRNA-Targeting
15 Apr 2026 //
BIOSPACE
Denali Therapeutics Showcases Enzyme Transportvehicle Programs
02 Feb 2026 //
GLOBENEWSWIRE
Denali Therapeutics To Present Enzyme Transport Vehicle Data
29 Jan 2026 //
GLOBENEWSWIRE
Sanofi Keeps Mum On Denali Pact After Scrapping Final RIPK1 Drug
29 Jan 2026 //
FIERCE BIOTECH
Denali Therapeutics Prices Common Stock and Pre-Funded Warrants
10 Dec 2025 //
GLOBENEWSWIRE
Denali Pharma Plans Stock Offering And Pre-Funded Warrants
09 Dec 2025 //
GLOBENEWSWIRE
Denali Pharma Reveals Leadership Changes
06 Nov 2025 //
GLOBENEWSWIRE
Denali Therapeutics Q2 2025 Financial Results and Highlights
11 Aug 2025 //
GLOBENEWSWIRE
Denali Therapeutics Reports Q4 and Full Year 2024 Results
27 Feb 2025 //
GLOBENEWSWIRE
Denali Shares 2025 Milestones For Neurodegeneration & LSD Portfolio
13 Jan 2025 //
GLOBENEWSWIRE
Denali Therapeutics` ALS drug fails in mid-to-late stage trial
07 Jan 2025 //
REUTERS
Denali Reports Results For Regimen G In Healey ALS Trial
06 Jan 2025 //
GLOBENEWSWIRE
Denali Doses First Participant in Ph 2a LRRK2 Inhibitor Study
05 Dec 2024 //
GLOBENEWSWIRE
Denali Therapeutics Reports Q3 2024 Financials & Highlights
06 Nov 2024 //
GLOBENEWSWIRE
Denali-Sanofi scraps mid-stage study for multiple sclerosis drug
11 Oct 2024 //
REUTERS
Denali to File for FDA Accelerated Approval of Tividenofusp Alfa for MPS II
03 Sep 2024 //
GLOBENEWSWIRE
Denali Reports Q2 2024 Results And Business Highlights
01 Aug 2024 //
GLOBENEWSWIRE
GSK, Sanofi, Denali take part in FNIH Parkinson’s biomarker project
17 Jul 2024 //
FIERCE BIOTECH
Denali`s DNL126 Selected For FDA START For MPS IIIA Acceleration
03 Jun 2024 //
GLOBENEWSWIRE
Denali Therapeutics Q1 2024 Results and Highlights
07 May 2024 //
GLOBENEWSWIRE
Denali: Enrollment Complete For DNL343 ALS Trial Regimen G
01 May 2024 //
GLOBENEWSWIRE
Denali Therapeutics Announces $500 million Private Placement Equity Financing
27 Feb 2024 //
GLOBENEWSWIRE
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
GLOBENEWSWIRE
Amid pivot, Denali Therapeutics sends staff packing
26 Feb 2024 //
FIERCE BIOTECH
Denali-Sanofi`s ALS drug fails to meet mid-stage trial goal
17 Feb 2024 //
REUTERS
Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
16 Feb 2024 //
PRESS RELEASE
Denali reports a PhII ALS fail as RIPK1 deal with Sanofi hits another bump
16 Feb 2024 //
ENDPTS
Denali Therapeutics Announces Presentations on Its Investigational BBB
01 Feb 2024 //
GLOBENEWSWIRE
Denali Therapeutics Announces Key Anticipated 2024 Milestones
08 Jan 2024 //
GLOBENEWSWIRE
Investors in Denali from three years ago are still down 74%
14 Dec 2023 //
SIMPLY WALL
Denali Reports Third Quarter 2023 Financial Results and Business Highlights
07 Nov 2023 //
GLOBENEWSWIRE
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310
30 Aug 2023 //
GLOBENEWSWIRE
Denali, Takeda scrap PhI Alzheimer`s drug due to safety signals
09 Aug 2023 //
ENDPTS
Denali Therapeutics Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
PRESS RELEASE
Biogen trims Denali-partnered Parkinson`s program in half
06 Jun 2023 //
FIERCE BIOTECH
Why Shares of Denali Therapeutics Are Up Monday
15 May 2023 //
NASDAQ
Denali Therapeutics Reports 1Q 2023 FYR and Business Highlights
08 May 2023 //
GLOBENEWSWIRE
Biogen Exercises Option with Denali to Develop Antibody Transport Vehicle Program
12 Apr 2023 //
GLOBENEWSWIRE
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
27 Feb 2023 //
GLOBENEWSWIRE
Denali Therapeutics Announces Presentations on ETV Development Programs
15 Feb 2023 //
GLOBENEWSWIRE
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Trial
25 Jan 2023 //
GLOBENEWSWIRE
FDA adcomm votes in favor of antifungal; Denali gets $25M from Sanofi MS trial
25 Jan 2023 //
ENDPTS
Denali Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio
09 Jan 2023 //
GLOBENEWSWIRE
Denali Therapeutics Announces DNL343 Interim Ph1b Data in ALS
05 Dec 2022 //
GLOBENEWSWIRE
Denali Therapeutics Reports 3Q FYR and Business Highlights
03 Nov 2022 //
GLOBENEWSWIRE
Denali Announces Ph 1/2 Study Single Dose Healthy Volunteer Data TAK-594/DNL593
01 Nov 2022 //
GLOBENEWSWIRE
Denali Therapeutics Announces Closing of a $316 Million Public Offering
24 Oct 2022 //
GLOBENEWSWIRE
Denali Therapeutics Announces Pricing of $275 Million Public Offering
19 Oct 2022 //
GLOBENEWSWIRE
Denali Therapeutics Announces Proposed Offering of Common Stock
18 Oct 2022 //
GLOBENEWSWIRE
Investors in Denali have made a decent return of 100% over the past three years
10 Oct 2022 //
FINANCE YAHOO
Biogen & Denali Announce Initiation of the Phase 3 LIGHTHOUSE Study
03 Oct 2022 //
PRESS RELEASE
Biogen, Denali begin late-stage testing of Parkinson’s drug
03 Oct 2022 //
BIOPHARMADIVE
Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?
29 Sep 2022 //
NASDAQ
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310
31 Aug 2022 //
GLOBENEWSWIRE
Denali Tx Reports Second Quarter 2022 Financial Results and Business Highlights
08 Aug 2022 //
GLOBENEWSWIRE
Biogen, Denali begin Phase IIb trial of Parkinson’s disease therapy
01 Jun 2022 //
CLINICALTRIALSARENA
Denali Tx, Biogen Initaites PIIb Study of LRRK2 Inhibitor in Parkinson`s Disease
31 May 2022 //
GLOBENEWSWIRE
PharmEnable announces multi-target collaboration with Denali Therapeutics
30 May 2022 //
PRNEWSWIRE
Denali Therapeutics Reports First Quarter 2022 Financial Results
05 May 2022 //
GLOBENEWSWIRE
Denali Announces Achievement of RIPK1 Milestone for PII Trial Initiation in ALS
02 May 2022 //
GLOBENEWSWIRE
